Voyager Therapeutics

Voyager Therapeutics

Develops genetic medicines for neurological diseases

About Voyager Therapeutics

Simplify's Rating
Why Voyager Therapeutics is rated
A
Rated A on Competitive Edge
Rated B on Growth Potential
Rated A+ on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

IPO

Total Funding

$102.1M

Headquarters

Cambridge, Massachusetts

Founded

2014

Overview

Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like amyotrophic lateral sclerosis (ALS). Their approach involves using a proprietary platform that utilizes adeno-associated virus (AAV) capsids to deliver genetic material directly to the brain through intravenous dosing, overcoming the challenge of the blood-brain barrier. Unlike many competitors, Voyager focuses on creating treatments that are specifically designed to address severe neurological conditions, and they emphasize collaboration with larger pharmaceutical companies to enhance their research and development efforts. The company's goal is to provide transformative therapies that significantly improve the lives of patients suffering from these debilitating diseases.

📈
Significant Headcount Growth
Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Novartis boosts Voyager's pipeline for SMA and neurological conditions.
  • FDA's approval of gene therapy for sickle cell disease signals potential regulatory success.
  • Voyager's GBA1 program with Neurocrine could advance Parkinson's disease treatments.

What critics are saying

  • Novartis's legal issues may delay Voyager's SMA gene therapy collaboration.
  • New CMO Toby Ferguson might disrupt projects if his vision differs from current strategies.
  • Electric pulse gene delivery could outpace Voyager's AAV methods, reducing competitiveness.

What makes Voyager Therapeutics unique

  • Voyager focuses on CNS diseases needing new therapies, like Parkinson's and ALS.
  • Their proprietary AAV capsid platform enables gene delivery across the blood-brain barrier.
  • Voyager's R&D model emphasizes partnerships, enhancing resources and expertise for gene therapies.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$102.1M

Above

Industry Average

Funded Over

4 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

↑ 4%

1 year growth

↑ 6%

2 year growth

↑ 11%
Stock Titan
Feb 25th, 2025
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

Additionally, Voyager will participate in the Stifel 2025 Virtual CNS Forum, featuring a fireside chat on March 19, 2025, at 11:00 a.m. ET.

SMA News Today
Jan 3rd, 2025
Top 10 SMA news stories of 2024

At the start of 2024, Voyager Therapeutics announced that it would collaborate with Novartis to discover and develop next-generation gene therapies for SMA and other neurologic conditions.

MarketBeat
Sep 24th, 2024
Great Point Partners LLC Invests $12.67 Million in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Great Point Partners LLC invests $12.67 million in Voyager Therapeutics, Inc. (NASDAQ:VYGR).

CityBiz
Jun 13th, 2024
Voyager Therapeutics Appoints Nathan Jorgensen as Chief Financial Officer

Voyager Therapeutics appoints Nathan Jorgensen as Chief Financial Officer.

Securities.io
May 7th, 2024
Super Charging Gene Therapy With Electric Pulses

Improving Gene TherapyIn December 2023, the FDA made history by approving the first human gene therapy for sickle cell disease. This was quite a revolution and opened the way for much more gene therapy for other incurable diseases.One difficulty in all gene therapy procedures is getting enough of the intended genetic material delivered into the target cells. This can cause multiple issues, from too low gene modification to be efficient as a medicine to un-targeted cells being modified or immune reactions and side effects from too concentrated a dose. And, of course, using more than needed gene editing medicine is expensive.Luckily, researchers might have found a way to solve this issue, using electric pulses to boost the efficiency of gene transformation 40 times.Electricity For Gene EditingUsing electricity for gene modification is not really a new concept in itself, with electroporation a very ancient method used to create GMOs. However, in the case of this method, the damage inflicted on the cells by the very high voltage makes it only fit for modifying cell culture, bacteria, or plants, and not the gene inside a living animal or human.What the researchers at the University of Wisconsin–Madison have discovered is that gene therapies can be improved with a short pulse of electricity instead. This was done in collaboration between University of Wisconsin–Madison researchers ( Susan Hagness and John Booske and PhD student Yizhou Yao) and Hans Sollinger, a world-renowned transplant surgeon.Contrary to the more brutal electroporation method, the electric pulses are very quick, only 80 milliseconds long

Recently Posted Jobs

Sign up to get curated job recommendations

Voyager Therapeutics is Hiring for 4 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Voyager Therapeutics's jobs every few hours, so check again soon! Browse all jobs →